. 2025 Aug 19;28(5):93. doi: 10.1007/s11102-025-01564-7

Table 2.

Changes in metabolic biomarkers from baseline to 24 months during semaglutide treatment. ALAT = alanine aminotransferase, HbA1c = glycated hemoglobin A1c, tg = triglycerides, LDL = low-density lipoprotein, HDL = high-density lipoprotein

	Baseline mean ×/÷ SD [95%CI of SD]	6 months (𝚫 baseline) [95% CI]	12 months (𝚫 baseline) [95% CI]	24 months (𝚫 baseline) [95% CI]
ALAT (U/L)	34.1 ×/÷ 63.3% [32.0-523.8%]	−1.3 [–16.; 27.6]	−7.7 [–23.0; 28.7]	5.8 [–21.3; 89.6]
HbA1c (mmol/mol)	38.1 ×/÷ 11.6% [6.4–50.8%]	−4.1 [–7.3; −0.7]	−6.7 [–9.3; −3.7]	−6.4 [–9.9; −2.3]
TG (mmol/L)	2.2 ×/÷ 36.9% [19.5-222.8%]	−0.9 [–1.4; 0.0]	−1.0 [–1.6; − 0.1]	−1.0 [–1.8; 1.2]
LDL (mmol/L)	2.5 ×/÷ 30.3% [16.2-168.2%]	−0.3 [–0.9; 0.7]	−0.4 [–0.9; 0.4]	−0.5 [–0.7; − 0.3]
HDL (mmol/L)	1.1 ×/÷ 17.5% [9.6–82.7%]	−0.2 [–0.2; − 0.1]	−0.0 [–0.1; 0.0]	0.1 [–0.3; 0.6]

Baseline
mean ×/÷ SD [95%CI of SD]

6 months
(𝚫 baseline) [95% CI]

12 months
(𝚫 baseline) [95% CI]

24 months
(𝚫 baseline) [95% CI]

ALAT

(U/L)

34.1 ×/÷ 63.3% [32.0-523.8%]

−1.3

[–16.; 27.6]

−7.7

[–23.0; 28.7]

5.8

[–21.3; 89.6]

HbA1c

(mmol/mol)

38.1 ×/÷ 11.6% [6.4–50.8%]

−4.1

[–7.3; −0.7]

−6.7

[–9.3; −3.7]

−6.4

[–9.9; −2.3]

(mmol/L)

2.2 ×/÷ 36.9% [19.5-222.8%]

−0.9

[–1.4; 0.0]

−1.0

[–1.6; − 0.1]

−1.0

[–1.8; 1.2]

LDL

(mmol/L)

2.5 ×/÷ 30.3% [16.2-168.2%]

−0.3

[–0.9; 0.7]

−0.4

[–0.9; 0.4]

−0.5

[–0.7; − 0.3]

HDL

(mmol/L)

1.1 ×/÷ 17.5% [9.6–82.7%]

−0.2

[–0.2; − 0.1]

−0.0

[–0.1; 0.0]

0.1

[–0.3; 0.6]